Hydrophobically modified polysaccharide-based on polysialic acid nanoparticles as carriers for anticancer drugs

International Journal of Pharmaceutics

Volumn 520, Issue 1-2, 2017, Pages 111-118

  Jung, Bom ^a   Shim, Man Kyu ^a,b   Park, Min Ju ^a   Jang, Eun Hyang ^a   Yoon, Hong Yeol ^b   Kim, Kwangmeyung ^b   Kim, Jong Ho ^a  

^a Kyung Hee University   (South Korea)

^b Korea Institute of Science and Technology   (South Korea)

Author keywords

Doxorubicin; EPR effect; Nanoparticles; Polysialic acid; Targeted cancer therapy

Indexed keywords

1 (3 DIMETHYLAMINOPROPYL) 3 ETHYLCARBODIIMIDE; CHOLANIC ACID DERIVATIVE; DOXORUBICIN; N HYDROXYSUCCINIMIDE; NANOPARTICLE; POLYSACCHARIDE; POLYSIALIC ACID; ANTINEOPLASTIC AGENT; DRUG CARRIER; SIALIC ACID DERIVATIVE;

A-549 CELL LINE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE; ZETA POTENTIAL; ANIMAL; CELL SURVIVAL; CHEMICAL PHENOMENA; CHEMISTRY; DRUG EFFECTS; DRUG RELEASE; DRUG SCREENING; HUMAN; METABOLISM; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG CARRIERS; DRUG LIBERATION; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MICE; NANOPARTICLES; PARTICLE SIZE; SIALIC ACIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85011900736     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2017.01.055     Document Type: Article

References (23)

1. Bader, R.A., Silvers, A.L., Zhang, N., Polysialic acid-based micelles for encapsulation of hydrophobic drugs. Biomacromolecules 12 (2011), 314–320.
2. Barry, G.T., Goebel, W.F., Colominic acid, a substance of bacterial origin related to sialic acid. Nature, 179, 1957, 206.
3. Biswas, S., Torchilin, V.P., Nanopreparations for organelle-specific delivery in cancer. Adv. Drug Deliv. Rev. 66 (2014), 26–41.
4. Erbing, C., Granath, K., Kenne, L., Lindberg, B., A new method for the N-deacetylation of carbohydrates. Carbohydr. Res., 47, 1976.
5. Fang, J., Nakamura, H., Maeda, H., The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 63 (2011), 136–151.
6. Fernandes, A.I., Gregoriadis, G., Polysialylated asparaginase: preparation, activity and pharmacokinetics. Biochim. Biophys. Acta 1341 (1997), 26–34.
7. Fernandes, A.I., Gregoriadis, G., The effect of polysialylation on the immunogenicity and antigenicity of asparaginase: implication in its pharmacokinetics. Int. J. Pharm. 217 (2001), 215–224.
8. Gewirtz, D.A., A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 57 (1999), 727–741.
9. Gregoriadis, G., Fernandes, A., Mital, M., McCormack, B., Polysialic acids: potential in improving the stability and pharmacokinetics of proteins and other therapeutics. Cell. Mol. Life Sci.: CMLS 57 (2000), 1964–1969.
10. Iyer, A.K., Khaled, G., Fang, J., Maeda, H., Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today 11 (2006), 812–818.
11. Kim, J.H., Kim, Y.S., Kim, S., Park, J.H., Kim, K., Choi, K., Chung, H., Jeong, S.Y., Park, R.W., Kim, I.S., Kwon, I.C., Hydrophobically modified glycol chitosan nanoparticles as carriers for paclitaxel. J. Controll. Release 111 (2006), 228–234.
12. Koshkaryev, A., Thekkedath, R., Pagano, C., Meerovich, I., Torchilin, V.P., Targeting of lysosomes by liposomes modified with octadecyl-rhodamine B. J. Drug Target. 19 (2011), 606–614.
13. Koshkaryev, A., Piroyan, A., Torchilin, V.P., Increased apoptosis in cancer cells in vitro and in vivo by ceramides in transferrin-modified liposomes. Cancer. Biol. Ther. 13 (2012), 50–60.
14. Maeda, H., Greish, K., Fang, J., The EPR effect and polymeric drugs: a paradigm shift for cancer chemotherapy in the 21st century. Adv. Polym. Sci. 193 (2006), 103–121.
15. Maeda, H., Bharate, G.Y., Daruwalla, J., Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur. J. Pharm. Biopharm. 71 (2009), 409–419.
16. Maeda, H., The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 41 (2001), 189–207.
17. Maeda, H., SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv. Drug Deliv. Rev. 46 (2001), 169–185.
18. Seki, T., Fang, J., Maeda, H., Tumor-targeted macromolecular drug delivery based on the enhanced permeability and retention effect in solid tumor. Pharm. Perspect. Cancer Ther., 2009, 93–120.
19. Torchilin, V., Tumor delivery of macromolecular drugs based on the EPR effect. Adv. Drug Deliv. Rev. 63 (2011), 131–135.
20. Wilson, D.R., Zhang, N., Silvers, A.L., Forstner, M.B., Bader, R.A., Synthesis and evaluation of cyclosporine A-loaded polysialic acid-polycaprolactone micelles for rheumatoid arthritis. Eur. J. Pharm. Sci. 51 (2014), 146–156.
21. Wu, J.R., Zhan, X.B., Zheng, Z.Y., Zhang, H.T., Synthesis and characterization of polysialic Acid/carboxymethyl chitosan hydrogel with potential for drug delivery. Bioorg. Khim. 41 (2015), 627–632.
22. Zhang, N., Bader, R.A., Synthesis and characterization of polysialic acid-N-trimethyl chitosan nanoparticles for drug delivery. Nano LIFE 2 (2012), 1–11.
23. Zheng, Z.Y., Wang, S.Z., Li, G.S., Zhan, X.B., Lin, C.C., Wu, J.R., Zhu, L., A new polysialic acid production process based on dual-stage pH control and fed-batch fermentation for higher yield and resulting high molecular weight product. Appl. Microbiol. Biotechnol. 97 (2013), 2405–2412.